Erasca (ERAS) Cash from Investing Activities (2020 - 2026)
Erasca (ERAS) posted Cash from Investing Activities of -$243.8 million for Q1 2026, down 1086.73% on a QoQ basis from $24.7 million in Q4 2025, and down 811.6% year-over-year from $34.3 million in Q1 2025.
Erasca (ERAS) Cash from Investing Activities (2020 - 2026) Analysis & Trends
Erasca's Cash from Investing Activities history runs 7 years deep, the most recent figure standing at -$243.8 million for Q1 2026.
- Quarterly Cash from Investing Activities fell 811.6% year-over-year to -$243.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$177.7 million (down 34.27% YoY) and the FY2025 annual result came in at $100.4 million, up 164.12% from the prior year.
- Cash from Investing Activities was -$243.8 million for Q1 2026 at Erasca, down from $24.7 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $34.3 million in Q1 2025 and bottomed at -$243.8 million in Q1 2026.
- A 5-year average of -$27.2 million and a median of -$1.8 million in 2022 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities soared 920.18% — and 2024, when it tumbled 5561.98%.
- Erasca's Cash from Investing Activities stood at -$4.9 million in 2022, then jumped by 193.38% to $4.5 million in 2023, then surged by 397.62% to $22.6 million in 2024, then climbed by 9.26% to $24.7 million in 2025, then plunged by 1086.73% to -$243.8 million in 2026.
- Business Quant data shows ERAS's Cash from Investing Activities at -$243.8 million in Q1 2026, $24.7 million in Q4 2025, and $25.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,200.25 Bn | 66,199.96 Bn | - | - |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.75 Bn | 466.96 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.94 Bn | 114.69 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.87 Bn | 61.12 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.43 Bn | 62.43 Bn | - | - |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Erasca | 5.81 Bn | 5.57 Bn | - | -243.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -243.83 Mn |
| Mar 31, 2026 | -243.83 Mn |
| Dec 31, 2025 | 24.71 Mn |
| Dec 31, 2025 | 24.71 Mn |
| Sep 30, 2025 | 25.70 Mn |
| Sep 30, 2025 | 25.70 Mn |
| Jun 30, 2025 | 15.75 Mn |
| Jun 30, 2025 | 15.75 Mn |
| Mar 31, 2025 | 34.27 Mn |
| Mar 31, 2025 | 34.27 Mn |
| Dec 31, 2024 | 22.62 Mn |
| Dec 31, 2024 | 22.62 Mn |
| Sep 30, 2024 | -102.60 Mn |
| Sep 30, 2024 | -102.60 Mn |
| Jun 30, 2024 | -86.61 Mn |
| Jun 30, 2024 | -86.61 Mn |
| Mar 31, 2024 | 9.97 Mn |
| Mar 31, 2024 | 9.97 Mn |
| Dec 31, 2023 | 4.55 Mn |
| Dec 31, 2023 | 4.55 Mn |